Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

March 5, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 5, 2012 - Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US. CTP-499 is intended to be additive to the current standard of care, angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy, to prevent or slow progression of kidney damage in diabetic nephropathy and other types of chronic kidney disease.

“Kidney disease represents a major health concern, driven by higher rates of diabetes, obesity and an aging population. Despite available treatments, many patients progress to renal failure. The current pipeline for novel treatments is limited, and there is a need for more effective pharmacologic intervention to manage CKD and to slow disease progression. CTP-499 provides a new mechanism of action that has the potential to address this substantial unmet medical need,” said James Shipley, M.D., Chief Medical Officer of Concert Pharmaceuticals.

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, multi-center clinical trial to evaluate the safety and efficacy of CTP-499 in patients with type 2 diabetes and mild to moderate (stage 2/3) chronic kidney disease who demonstrate a loss of albumin into their urine. Such patients have an elevated risk for progression to end-stage renal disease as well as cardiovascular morbidity such as heart attack and stroke. Approximately 170 patients will be enrolled in the study. Following a stabilization period, patients will receive placebo or 600 mg of CTP-499 twice daily for 24 weeks. The primary endpoint is change in urine albumin to creatinine ratio (UACR) from pre-treatment baseline to post-treatment. Additional information about the Phase 2 clinical trial is available at

In 2011, Concert completed four Phase 1 clinical trials with CTP-499, including a multiple dose safety and tolerability study in patients with CKD, supporting selection of the patient dosing regimen of 600 mg BID for the Phase 2 study. CTP-499 was generally well-tolerated with the most common adverse event being mild, transient nausea. Concert expects to present findings from its safety and tolerability study in CKD patients in 2012.

CTP-499 is an analog of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX), an active metabolite of pentoxifylline. CTP-499, a potential first-in-class treatment for diabetic nephropathy, possesses a pleiotropic mechanism of action with anti-inflammatory, anti-oxidant and anti-fibrotic properties. Its unique qualities may enable it to intervene in the pathophysiology of diabetic nephropathy, other forms of kidney disease and fibrotic indications. CTP-499 was developed using Concert's DCE Platform™ to provide a new chemical entity with an improved pharmacokinetic profile compared to pentoxifylline. CTP-499 incorporates deuterium in selected positions in the molecule, which improves the metabolic stability of the compound.

About Diabetic Nephropathy

Diabetic nephropathy is a frequent consequence of diabetes and is the leading cause of CKD and need for dialysis in the US. The current standard of care for CKD is treatment with blood pressure lowering agents that affect the renin-angiotensin system, including ACEi and ARBs. Despite the availability of these treatments, many patients progress to renal failure with the need for dialysis. According to the US Renal Data System, the number of end-stage renal failure patients in the US doubled between 1994 and 2008.

About Deuterium Modification

Concert Pharmaceuticals specializes in the use of precision deuterium chemistry to create new chemical entities (NCEs) with unique properties based on known, pharmacologically active compounds. By selectively replacing one or more hydrogen atoms with deuterium, a stable and non-radioactive isotope of hydrogen, the company has been able to effect significant changes to the absorption, distribution, metabolism, or excretion (ADME) profile of a number of compounds with the potential for improvements in safety, tolerability, and/or efficacy.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company's DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert's approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit

Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.

Contact: Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg (Investors), 781-674-5284
Kathryn Morris (Media), 845-635-9828